Influence of LH-RH agonists on the growth and hormonal environment of breast and prostate cancer.
Patients with advanced breast cancer or advanced prostate cancer have been treated with an LH-RH-agonist ICI 118630. A chemical castration-like response has been achieved in all patients and is associated with clinical remission of the disease.
Nicholson
R I
RI
Walker
K J
KJ
D001943:Breast Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D002064:Buserelin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D017273:Goserelin; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D013739:Testosterone / Q000097:blood
D017273:Goserelin; D013739:Testosterone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D002064:Buserelin